Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort
LEADS Consortium, Angelina J. Polsinelli, Ryan J. Wonderlin, Dustin B. Hammers, Alex Pena Garcia, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Laurel Beckett, Sujuan Gao, Sophia Wang, Kala Kirby, Paige E. Logan, Paul Aisen, Jeffrey L. Dage, Tatiana Foroud, Percy Griffin, Leonardo Iaccarino, Joel H. Kramer, Robert KoeppeWalter A. Kukull, Renaud La Joie, Nidhi S. Mundada, Melissa E. Murray, Kelly Nudelman, David N. Soleimani-Meigooni, Malia Rumbaugh, Arthur W. Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Lawrence S. Honig, David T. Jones, Joseph Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily Rogalski, Steven Salloway, Sharon J. Sha, Raymond S. Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Bradford C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova
Dive into the research topics of 'Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort'. Together they form a unique fingerprint.